$ZVSA News

ZyVersa Therapeutics Q1 EPS $(0.22) Up From $(0.73) YoY

ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

ZyVersa Therapeutics Q3 EPS $(2.56) Down From $(2.43) YoY

ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

ZyVersa Highlights Review Of 172 Studies Linking Lipotoxicity To DKD Progression; Supports Therapeutic Targeting Of Lipid Metabolic Reprogramming

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

ZyVersa Therapeutics Q2 EPS $(0.46) Misses $(0.40) Estimate

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

ZyVersa Therapeutics Releases Mid-Year Shareholder Letter Highlighting Recent Corporate Developments And R&D Progress Including Closing Two Financial Transactions Providing Access To $12M In Capital

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds

Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?

ZyVersa Therapeutics Enters $2M Warrant Inducement Deal; Issues New Series A-4 Warrants for 6.1M Shares At $0.67 Exercise Price

ZyVersa Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 110.5%

ZyVersa Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 110.5%

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis

ZyVersa Therapeutics shares are trading higher after the company announced it provided regulatory and product support for an FDA-authorized emergency compassionate use of cholesterol efflux mediator VAR 200.

ZyVersa Therapeutics Provides Regulatory And Product Support For FDA-Authorized Emergency Compassionate Use Of Cholesterol Efflux Mediator VAR 200 In ApoCII Amyloidosis Patient

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)